<?xml version='1.0' encoding='utf-8'?>
<document id="27299937"><sentence text="Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling."><entity charOffset="68-77" id="DDI-PubMed.27299937.s1.e0" text="Naloxegol" /></sentence><sentence text="Naloxegol, a peripherally acting μ-opioid receptor antagonist for the treatment of opioid-induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P-glycoprotein (P-gp) transporter"><entity charOffset="0-9" id="DDI-PubMed.27299937.s2.e0" text="Naloxegol" /></sentence><sentence text=" By integrating in silico, preclinical, and clinical pharmacokinetic (PK) findings, minimal and full physiologically based pharmacokinetic (PBPK) models were developed to predict the drug-drug interaction (DDI) potential for naloxegol"><entity charOffset="225-234" id="DDI-PubMed.27299937.s3.e0" text="naloxegol" /></sentence><sentence text=" The models reasonably predicted the observed changes in naloxegol exposure with ketoconazole (increase of 13"><entity charOffset="57-66" id="DDI-PubMed.27299937.s4.e0" text="naloxegol" /><entity charOffset="81-93" id="DDI-PubMed.27299937.s4.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.27299937.s4.e0" e2="DDI-PubMed.27299937.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27299937.s4.e0" e2="DDI-PubMed.27299937.s4.e1" /></sentence><sentence text="1-fold predicted vs" /><sentence text=" 12" /><sentence text="9-fold observed), diltiazem (increase of 2" /><sentence text="8-fold predicted vs" /><sentence text=" 3" /><sentence text="4-fold observed), rifampin (reduction of 76% predicted vs"><entity charOffset="18-26" id="DDI-PubMed.27299937.s10.e0" text="rifampin" /></sentence><sentence text=" 89% observed), and quinidine (increase of 1"><entity charOffset="20-29" id="DDI-PubMed.27299937.s11.e0" text="quinidine" /></sentence><sentence text="2-fold predicted vs" /><sentence text=" 1" /><sentence text="4-fold observed)" /><sentence text=" The moderate CYP3A4 inducer efavirenz was predicted to reduce naloxegol exposure by ∼50%, whereas weak CYP3A inhibitors were predicted to minimally affect exposure"><entity charOffset="29-38" id="DDI-PubMed.27299937.s15.e0" text="efavirenz" /><entity charOffset="63-72" id="DDI-PubMed.27299937.s15.e1" text="naloxegol" /><pair ddi="false" e1="DDI-PubMed.27299937.s15.e0" e2="DDI-PubMed.27299937.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27299937.s15.e0" e2="DDI-PubMed.27299937.s15.e1" /></sentence><sentence text=" In summary, the PBPK models reasonably estimated interactions with various CYP3A modulators and can be used to guide dosing in clinical practice when naloxegol is coadministered with such agents"><entity charOffset="151-160" id="DDI-PubMed.27299937.s16.e0" text="naloxegol" /></sentence><sentence text="" /></document>